Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade

Oida, Takatsugu; Mimatsu, Kenji; Kano, Hiso; Kawasaki, Atsushi; Kuboi, Youichi; Fukino, Nobutada; Amano, Sadao

doi:10.3748/wjg.v16.i6.740

Cited by 23 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients achieved obvious and sustained symptom remission, and six of the seven patients did not suffer from effusion recurrence before death. Similar studies using intrapericardial cisplatin reported median survival times of 84 ± 39 days [30] and 120 ± 71 days (range, 68–268 days) [31]. Our results in this group of patients suggest that intrapericardial BEV may be more effective than other therapies in treating MPCE.…”

Section: Discussionsupporting

confidence: 78%

See 1 more Smart Citation

Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients

et al. 2016

View full text Add to dashboard Cite

We evaluated the safety and efficacy of intrapericardial bevacizumab (BEV) for treating symptomatic malignant pericardiac effusion (MPCE) in seven advanced cancer patients. All patients had previously undergone multiple lines of systemic therapy. Each patient received paracentesis and intrapericardial infusions of 100 or 200 mg of BEV every two weeks. Systemic treatments for primary tumors continued for all patients during BEV treatment. Of the seven patients, three achieved a complete response, two achieved a partial response, and two showed no response with regard to MPCE after BEV infusion. The median overall survival time was 168 days (range, 22-224 days). In six of the seven patients, effusion did not recur before death. Toxicity associated with BEV treatment was mild and manageable in all patients. This study provides preliminary evidence that intrapericardial BEV may be an effective and safe treatment for MPCE in patients with advanced cancers.

show abstract

Section: Discussionsupporting

confidence: 78%

“…Maisch et al [30] and Oida et al [31] reported nausea in most patients who received cisplatin infusions. In contrast, no hematological toxicity, hepatotoxicity, or nephrotoxicity was observed in any of the patients in our study after BEV treatment.…”

Section: Discussionmentioning

confidence: 99%

Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“… 5 Cisplatin is the most common agent for treating malignant effusion because of its high patient response rate; however, it is associated with common chemotherapeutic adverse events. 6 Chen et al reported a complete remission rate of 71.4% in non-small-cell lung cancer (NSCLC) patients treated with etoposide and cisplatin by pericardial perfusion to alleviate MPCE. 7 However, the authors also reported MPCE recurrence and gastrointestinal and hematological toxicities in most patients.…”

Section: Discussionmentioning

confidence: 99%

Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review

Chen

Zhang

Shi

et al. 2015

OTT

View full text Add to dashboard Cite

Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors, and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by unsatisfactory therapeutic effects and serious adverse events. We report a patient with MPCE who was treated with bevacizumab by pericardial perfusion, resulting in a complete response. This case supports the use of intrapericardial bevacizumab as a potential treatment for MPCE.

show abstract

“…Several chemotherapeutic agents have been used for this scope, but the most used are platinum and triethylenethiophosphoramide (thiotepa), an anticancer agent with sclerosing properties. Intrapericardial cis-platinum or carboplatinum, with different schedules (10 mg over 5 continuous days, 10 mg over 3 days, 30 or 50 mg in single injection) has been used for 30 years with good results in various tumors, mostly in lung cancer pericarditis [60][61][62][63][64][65][66][67][68]. In a study on nine patients with various tumors, Tomkowski had two long-lasting responses, but most of the patients died of cancer within 3 months, and in all of the seven patients who had an autopsy, neoplastic pericardial involvement was found even without pericardial effusion [62].…”

Section: Antineoplastic Treatmentsmentioning

confidence: 99%

2015 update on the diagnosis and management of neoplastic pericardial disease

Lestuzzi

Berretta

Tomkowski³

2015

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

The best approach in diagnosis and treatment of neoplastic pericardial disease has not been defined yet. The authors report the most recent literature about the new diagnostic techniques that are useful to improve the diagnosis. The literature about the therapeutic options is critically reviewed, in order to give suggestions of use to the clinical practice. Pericardial effusion may require urgent drainage; the solid component, however, becomes predominant in some cases. Neoplastic pericardial disease should be assessed following oncologic criteria evaluation of the neoplastic burden; outcome classified as complete or partial response, stable or progressive disease and - in cases with progression - event-free survival. Systemic chemotherapy may be effective in lymphomas and possibly in breast carcinomas. Intrapericardial chemotherapy with systemic chemotherapy is the treatment of choice in lung cancer. Pericardial window with systemic chemotherapy is also effective in preventing the accumulation of large amount of fluid.

show abstract

Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade

Abstract: Pericardiocentesis along with catheter drainage appears to be a safe and effective for pericardial malignant effusion and tamponade, and cisplatin instillation prevents recurrence.

Cited by 23 publications

References 18 publications

Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients

Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients

Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review

2015 update on the diagnosis and management of neoplastic pericardial disease

Contact Info

Product

Resources

About